RxDoctor Payments DataLook up a doctor →

Steven Barag, DO

Family Medicine · Rancho Cucamonga, CANPI 1366444838

Payments from drug & device makers

$1,815,970in general payments, 2019–2025

Across 2,216 payments — averaging $819.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$884K
  • AbbVie$174K
  • Pfizer$169K
  • AstraZeneca$159K
  • Novo Nordisk AS$144K
  • Bayer$114K
  • plus $172K from 54 others
$24,369in research payments, 2019–2025

Across 9 payments — averaging $2707.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$24K
  • Novo Nordisk$48

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly66$883,612
AbbVie(2 entities)227$174,351
Pfizer138$168,613
AstraZeneca(2 entities)123$158,973
Novo Nordisk AS635$144,366
Bayer107$113,900
Janssen Research & Development, LLC11$53,039
Sanofi-aventis U.S. LLC52$26,132
Esperion Therapeutics, Inc.78$22,205
Boehringer Ingelheim30$20,104
Sanofi US Services Inc.4$12,157
Kowa Research Institute, Inc.19$11,867
Amgen(2 entities)47$8,391
Acerus Pharmaceuticals Corporation7$3,856
Novo Nordisk95$1,976
Antares Pharma, Inc.74$1,581
Biohaven Pharmaceuticals, Inc.12$1,568
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC47$740
Kowa Pharmaceuticals America, Inc.42$693
Lilly USA, LLC28$601
Amarin Pharma, Inc.34$496
Johnson & Johnson(2 entities)30$486
GSK19$460
Takeda Pharmaceuticals U.S.A., Inc.29$436
Arbor Pharmaceuticals, Inc.21$329
Abbott18$326
Merck15$280
Sumitomo Pharma America, Inc.14$273
Astellas Pharma US Inc7$270
Phathom Pharmaceuticals, Inc.5$235
Biohaven Pharmaceutical Holding Company Ltd.11$231
Eisai Inc.10$177
Currax Pharmaceuticals LLC13$175
E.r. Squibb & Sons, L.L.C.7$162
Sunovion Pharmaceuticals Inc.8$157
Galderma Laboratories, L.p.1$148
Novartis8$145
Teva Pharmaceuticals USA, Inc.7$144
Kyowa Kirin, Inc.2$138
Zyla Life Sciences, Inc.22$135
Vertiflex, Inc.1$125
Exact Sciences6$114
Halozyme Inc5$111
Genentech USA, Inc.6$105
Melinta Therapeutics, LLC4$103
Shield Therapeutics Inc3$98
Medicure Pharma Inc.2$91
Corcept Therapeutics4$84
Cequr Corporation1$73
Upsher-smith Laboratories LLC3$71
Corium, LLC3$71
Idorsia Pharmaceuticals US Inc3$65
IBSA Pharma Inc.3$64
Almatica Pharma LLC3$61
Aytu Biopharma, Inc.4$58
Lundbeck LLC2$54
Optinose US, Inc.2$53
Clarus Therapeutics Inc.3$50
Endo Pharmaceuticals Inc.3$46
Ferring Pharmaceuticals Inc.3$44

How this compares

$1,815,970 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Medicare billing

Part B allowed, 2024
$74,726
Medicare patients
237
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Rancho Cucamonga

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →